药物经济学评价在医保支付中应用的国际经验  

International Experience of Application of Pharmacoeconomics Evaluation in Medical Insurance

作　　者：董朝晖[1] 钟军[2] DONG Zhao-hui;ZHONG Jun(Institute of Social Security,the Ministry of Human Resources and Social Security,Beijing 100029,China;School of Public Health,Peking University,Beijing 100191,China)

机构地区：[1]人力资源和社会保障部社会保障研究所,北京100029 [2]北京大学公共卫生学院,北京100191

出　　处：《临床药物治疗杂志》2014年第S01期17-20,60,共5页Clinical Medication Journal

摘　　要：药物经济学评价在新药定价、医保目录评审和医保支付政策中发挥着重要作用。本文首先介绍新药进入医保支付的评价思路;然后以澳大利亚、加拿大和英国的药品评审为例,着重介绍药品进入医保支付的评审组织结构、评审流程;最后介绍药品评审结果在医保支付政策中的应用。Pharmacoeconomics evaluation plays an important role in pricing,listing,and medical insurance payment of medicine.In this paper,we described the evaluation framework of new drug for medical insurance listing and payment.Then we introduced the organization and working process of new drug review in Australia,Canada and UK.And ifnaly the application of the drug review result in medical insurance was discussed.

关 键 词：药物经济学评价 药品评审 医保支付 

分 类 号：R978.7[医药卫生—药品] R512.62[医药卫生—药学]